5.21
-0.43 (-7.69%)
| Previous Close | 5.64 |
| Open | 5.61 |
| Volume | 604,524 |
| Avg. Volume (3M) | 658,340 |
| Market Cap | 169,323,712 |
| Price / Sales | 52.50 |
| Price / Book | 1.51 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.78 |
| Total Debt/Equity (MRQ) | 0.03% |
| Current Ratio (MRQ) | 20.34 |
| Operating Cash Flow (TTM) | -50.76 M |
| Levered Free Cash Flow (TTM) | -33.03 M |
| Return on Assets (TTM) | -24.05% |
| Return on Equity (TTM) | -34.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sagimet Biosciences Inc. - Seri | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.03% |
| % Held by Institutions | 44.74% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Citizens, 572.24%) | Buy |
| Median | 28.00 (437.79%) | |
| Low | 8.00 (Barclays, 53.65%) | Hold |
| Average | 24.75 (375.37%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 6.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 03 Feb 2026 | 27.00 (418.58%) | Buy | 6.56 |
| HC Wainwright & Co. | 03 Feb 2026 | 29.00 (457.00%) | Buy | 6.56 |
| Barclays | 28 Jan 2026 | 8.00 (53.65%) | Hold | 5.86 |
| Citizens | 14 Nov 2025 | 35.00 (572.24%) | Buy | 7.75 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |